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Activator protein 1 (AP-1) contributes to EpCAMdependent breast cancer invasion
Narendra V Sankpal1, John D Mayfield1, Mike W Willman1, Timothy P Fleming1,2 and William E Gillanders1,2*

Abstract
Introduction: EpCAM is a cell-surface glycoprotein that is overexpressed in the majority of epithelial carcinomas.
However, the functional role of EpCAM in regulating cancer invasion remains controversial, and the mechanism(s)
underlying EpCAM-mediated regulation of breast cancer invasion remain to be defined.
Methods: EpCAM expression was manipulated in breast cancer cell lines using RNA interference and cDNA
expression constructs. Recombinant EpCAM was used to rescue EpCAM signaling following specific ablation of
EpCAM. Protein and gene expression, invasion, transcription factor activity, and protein phosphorylation were
measured using standard molecular biology techniques.
Results: In loss-of-function, and gain-of-function experiments we demonstrate that EpCAM expression is associated
with increased breast cancer invasion in vitro and in vivo. We demonstrate further that specific ablation of EpCAM
expression is associated with decreased activator protein-1 (AP-1) transcription factor activity. Phosphoprotein
analyses confirm that specific ablation of EpCAM is associated with decreased phosphorylation of the AP-1 subunit
c-Jun. Recombinant soluble extracellular EpCAM (rEpCAM) is able to rescue invasion, AP-1 transcription factor
activity, and c-Jun phosphorylation in a dose-dependent fashion. Pharmacologic inhibitors, and constitutively active
constructs of the c-Jun N-terminal kinase (JNK) signal transduction pathway, suggest that the impact of EpCAM
expression on AP-1 transcription factor activity is mediated through the JNK pathway. In functional rescue
experiments, forced expression of c-Jun rescues invasion in breast cancer cells following specific ablation of
EpCAM.
Conclusions: These data demonstrate for the first time that EpCAM expression can influence the JNK/AP-1 signal
transduction pathway, and suggest that modulation of AP-1 transcription factor activity contributes to EpCAMdependent breast cancer invasion. These data have important implications for the design and application of
molecular therapies targeting EpCAM.

Introduction
The epithelial cell adhesion molecule (EpCAM) is a type
I transmembrane protein that is localized to the basolateral membrane in the majority of normal epithelial tissues [1]. The functional role of EpCAM in cell adhesion
was the focus of early studies, and EpCAM has been
demonstrated to be a calcium-independent homophilic
cell adhesion molecule [2]. Recent studies have also
demonstrated a role for EpCAM in cell signaling, proliferation and invasion [3-7]. EpCAM is perhaps best
known for the fact that it is overexpressed in the
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majority of human epithelial cancers including colorectal, breast, gastric, prostate, ovarian, and lung cancers
[8,9]. EpCAM was the first human tumor-associated
antigen to be identified with monoclonal antibodies
[10], and was the first target of monoclonal antibody
therapy in humans [11]. Although initial results have
been disappointing, a number of second-generation
molecular therapies are currently under development
[12-17]. Despite this intense interest in EpCAM as a target for molecular therapy, there have been limited
attempts to define the functional role of EpCAM in cancer biology.
EpCAM expression in primary cancer specimens has
been studied extensively, and a number of studies in the
surgical pathology literature have evaluated the
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association between EpCAM expression and prognosis.
One inconsistency in the literature is that EpCAM
expression in primary cancer specimens appears to be
associated with a favorable prognosis in some cancer
types, and an unfavorable prognosis in other cancer
types. For instance, EpCAM expression in primary
breast cancers appears to be associated with decreased
patient survival [8,18-20]. However, EpCAM expression
in colorectal cancer appears to be associated with
improved patient survival [21]. Additional studies in
other cancer types have suggested an association with
improved patient survival in esophageal cancer [22], gastric cancer [23], and renal cell carcinoma [24,25], and an
association with decreased patient survival in ovarian
cancer [26], gall bladder cancer [27], and pancreatic cancer [28]. Although these studies are far from definitive,
taken together, they do suggest a cancer type-specific
role for EpCAM in cancer biology and invasion. This
inconsistency is paralleled in functional studies of
EpCAM biology performed in vitro. Loss-of-function
analyses using RNA interference suggest that EpCAM
expression is associated with increased invasion in
breast cancer [4], and gain-of-function analyses in colorectal and lung cancers suggest that EpCAM expression
is associated with decreased cancer invasion in these
cancer types [29,30]. A better understanding of the relation between EpCAM and cancer invasion will clearly
facilitate the rational design, and successful application
of molecular therapies targeting EpCAM in epithelial
carcinomas.
In this study we confirm that EpCAM expression is
associated with increased breast cancer invasion in vitro
and in vivo. In mechanistic studies, we demonstrate for
the first time that EpCAM expression can modulate the
c-Jun N-terminal kinase (JNK)/activator protein 1 (AP1) signal transduction pathway and target genes. These
observations provide important insights into the downstream mediators of EpCAM signaling, and the impact
of EpCAM expression on breast cancer invasion and
prognosis.

Materials and methods
Cell culture

The MDA-231 and MCF-7 breast cancer cell lines were
obtained from the American Type Culture Collection
(ATCC, Rockville, MD, USA). The CA1a breast cancer
cell line was obtained from Dr. Fred Miller at Wayne
State University (Detroit, MI, USA).
RNA interference and lentivirus generation

The lentiviral construct pSicoR and related expression
vectors were obtained from Dr. Tyler Jacks (Massachusetts Institute of Technology, Boston, MA, USA) [31].
Two shRNA target sequences specific for EpCAM (sh1,
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sh2) and a scrambled control sequence were cloned into
the pSicoR-puromycin vector as previously described
[32]. shRNA constructs were transfected into HEK293T
cells with VSVG and Δ8.9, and viral supernatants were
collected at 48 and 72 hours to transduce cells.
Plasmids and transfection

EpCAM cDNA was cloned from the MCF-7 breast cancer cell line. The c-Jun expression construct was
obtained from Dr. R. Lee at the University of Virginia
(Charlottesville, VA, USA). HA-MEKK1 was obtained
from Dr. J. Avruch at Massachusetts General Hospital
(Cambridge, MA, USA). Constructs from the JNK signal
transduction pathway including pcDNA3 FLAG-MKK7/
JNK1, pcDNA3 FLAG-MKK7, and pcDNA3 FLAGJNK1 were obtained from Addgene (Cambridge, MA,
USA). Cells were transfected with FuGENE-HD (Roche,
Indianapolis, IN, USA) or Lipofectamine LTX (Invitrogen, Carlsbad, CA, USA) as recommended by the
manufacturer.
Invasion assay

For invasion assays, stably transduced cells (4 × 10 4 )
were added to matrigel transwell invasion chambers or
control transwell chambers (BD Biosciences San Jose
CA, USA) and incubated for 24 to 72 hours with chemoattractant media (MEGM Clonetics, Walkersville,
MD, USA) supplemented with growth factors. Cells
invading through the matrigel or control membranes
were fixed using 70% ethanol, stained with 0.1% crystal
violet and photographed in four fields to cover the
entire area. Cells were counted from all fields by a
scientist blinded to the experimental conditions.
Tumor challenge

Six- to eight-week-old female nude mice were used for
tumor challenge experiments. All mice were housed in
pathogen-free facilities accredited by the Association
for Assessment and Accreditation of Laboratory Animal Care. Animal use protocols were approved by the
Washington University Animal Studies Committee.
MDA-231 breast cancer cells stably transduced with
scrambled control shRNA construct (SCR) and sh2
lentiviral shRNA constructs were harvested at 70 to
90% confluence. A 1 × 10 7 sample of MDA-231 cells
were resuspended in matrigel and injected into nude
mice in a total volume of 200 μL (n = 10 per group).
The right flank was injected with MDA-231(SCR) cells
and the left flank was injected with MDA-231(sh2)
cells. Tumor size was measured by electronic calipers
every three to five days until 45 days. At the time of
sacrifice, tumors were stored in formalin and submitted to an institutional core facility for H&E staining
and evaluation.
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Cell cycle analysis and MTT proliferation assay

Stably transduced MDA-231 cells were plated in culture
media at 0.5 × 106 cells/mL. After 24 hours, the culture
media was changed, and cells were pulse-labeled with
BrdU (final concentration, 1 μM) for 30 minutes. Cells
were washed with 1 × PBS and fixed with 70% cold
ethanol. For staining, cells were washed 1 × with PBS
with 0.1% BSA, and 0.1% Tween 20 and digested with
DNAse for 30 minutes. The cells were washed again
and then incubated with BrdU primary antibody (Becton
Dickinson Immunocytometry Systems, San Jose, CA,
USA) and fluorescein isothiocyanate (FITC) GAM secondary antibody (Becton Dickinson, San Jose, CA, USA).
Cell cycle analyses were performed using the ModFit LT
software (Topsham, ME, USA). For MTT assays, 5,000
cells were plated in 96-well plates in triplicate. After culture for the indicated time, MTT assays were preformed
using a Vibrant MTT cell proliferation assay kit (Invitrogen, Carlsbad CA, USA). The optical density at 570
nm was measured using a microplate reader.
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(Applied Biosystems, Foster City CA, USA). Primer
sequences of genes are available upon request. Each
reaction was performed in triplicate, and the data is
representative of two independent RNA preparations.
Multiplex phosphoprotein assay

For the multiplex phosphoprotein assay, CA1a cells
were starved for 12 hours in serum-free media and treated with and without 100 ng/mL EGF for 15 minutes.
Protein lysates were prepared using a cell lysis kit (BioRad, Hercules, CA, USA). Protein concentration was
measured using a BCA protein assay (Pierce, Rockford,
IL, USA). The presence of phosphorylated Akt (Ser473),
c-Jun (Ser63/73), and JNK (Thr183/Tyr185) were
detected by multiplex phosphoprotein assay (Bio-Rad,
Hercules, CA, USA) according to the manufacturer’s
protocol. Data are expressed as mean ± standard error
of the mean of triplicate values from separate
experiments.
Immunoblots

Flow cytometry

EpCAM expression levels were measured by flow cytometry using phycoerythrin-labeled EpCAM antibody
with a FACScan flow cytometer (BD Biosciences, San
Jose, CA, USA; #347211). EpCAM expression was quantified as mean fluorescence intensity (MFI).
Luciferase reporter assay

The luciferase reporter constructs pTA-Luc (empty vector control), pTA-AP-1-Luc (AP-1 reporter), and pRLTK-Luc (transfection control) were obtained form Clontech Laboratories (Mountain View, CA, USA). A 400 ng
sample of pTA-Luc or pTA-AP-1-Luc and 20 ng of
pRL-TK-Luc were transiently transfected into cell lines,
plated in triplicate using either Lipofectamine-LTX
(Invitrogen Carlsbad CA, USA) or FuGENE-HD (Roche,
Indianapolis, IN, USA). The next day, cells were incubated with serum-free media. After 24 hours, cells were
stimulated with phorbol-myristate acetate (PMA), and/
or epidermal growth factor (EGF) for an additional 16
hours as indicated. Reporter activity was determined
using the Dual-Luciferase kit (Promega, Madison, WI,
USA). Reporter activity was measured as luminescence
using a luminometer and quantified as relative light
units (RLU).
cDNA synthesis and real-time RT-PCR analysis

RNA was purified from cell lines using RNAeasy (Qiagen, Valencia, CA, USA). Three micrograms of RNA
was reverse transcribed using a copy DNA (cDNA)
synthesis kit (Ambion, Austin, TX, USA). Quantitative
mRNA expression was measured using SYBR green
chemistry and an ABI Prism 7700 Sequence Detector

For phosphoprotein immunoblots, cells were cultured
overnight in serum-free media and stimulated with 25
μg/mL anisomycin for 30 minutes, washed with ice-cold
PBS and lysed in cell lysis buffer (Cell Signaling Technology, Danvers, MA, USA). The protein concentration
was measured using the BCA protein assay (Pierce,
Rockford, IL, USA). A 30 to 50 μg sample of protein
was subjected to SDS-PAGE (NuPAGE, Invitrogen,
Carlsbad, CA, USA), and transferred by electrophoresis
to a polyvinylidene fluoride (PVDF) membrane. Antibodies were obtained from Santa Cruz Biotechnology
(Santa Cruz, CA, USA) (EpCAM, #sc-25308; JNK, #sc571, #sc-474; c-Jun, #sc-1694; HA, #sc-7392; actin, #sc1615), Sigma-Aldrich (Saint Louis, MO, USA) (FLAG,
#F3165), and Cell Signaling Technology (Danvers, MA,
USA) (phospho-JNK, #9255; phospho-c-Jun ser73,
#9164; SOD1, #2770). Signal detection was performed
using the ECL chemiluminescent immunodetection system (Applied Biosystems, Foster City, CA, USA). Immunoblot band density was analyzed using a Bio-Rad GS800 calibrated densitometer (Bio-Rad, Hercules, CA,
USA). For JNK immunoprecipitation, confluent cells
were serum starved overnight and immunoprecipitation
was carried out as described [33]. To quantify band density, immunoblots were developed on film and then
scanned and analyzed using ImageJ software (National
Institutes of Health, USA; http://rsbweb.nih.gov/ij/).
Plots of each lane were generated, and the area under
the peak corresponding to control samples (SCR) was
determined, and arbitrarily set at 1.0. The area under
the peak corresponding to experimental samples (sh2)
was then determined, and expressed relative to the corresponding control.
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Statistical analysis

The data are given as the mean values ± standard deviation. Statistical significance was evaluated by the Student’s t test. P values less than 0.05 were considered to
be statistically significant. Significant results are indicated in the appropriate figures with an asterisk.

Results
EpCAM expression is associated with breast cancer
invasion in vitro and in vivo

We have previously reported that specific ablation of
EpCAM decreases breast cancer invasion in vitro [4,7,32].
Many of these studies were performed with siRNA, and
the short duration of RNA interference associated with
these reagents precluded in vivo and/or mechanistic
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experiments. To confirm the impact of EpCAM on breast
cancer invasion in vivo, and to establish a functional rescue/gain-of-function model system for mechanistic studies, we generated stable breast cancer cell lines with
specific ablation of EpCAM expression using EpCAM-specific lentiviral shRNA constructs. Stable transduction of
breast cancer cell lines with EpCAM-specific lentiviral
shRNA constructs results in more than 90% reduction in
EpCAM protein expression as measured by immunoblot
(Figure 1a). Stable specific ablation of EpCAM in both
MDA-231 and CA1a breast cancer cell lines is also associated with a more than 80% decrease in invasion in matrigel transwell invasion assays (Figure 1b).
To control for off-target effects of RNA interference,
and establish a functional rescue model system for
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Figure 1 EpCAM expression is associated with breast cancer invasion in vitro. Epithelial cell adhesion molecule (EpCAM) expression was
specifically ablated in the breast cancer cell lines MDA-231 and CA1a by RNA interference and rescued, as indicated, by transient transfection
with an EpCAM cDNA resistant to RNA interference. (a) Specific ablation of EpCAM by shRNA results in a significant decrease in EpCAM protein
expression as measured by immunoblot. For each cell line, sh2 designates transduction with a lentiviral vector targeting the 3’ untranslated
region of EpCAM, while scrambled control shRNA construct (SCR) designates transduction with a lentiviral vector expressing a scrambled control
shRNA sequence. (b) Invasion was measured using a matrigel transwell invasion assay. After 24 to 72 hours, cells invading through the matrigel
membranes were fixed using 70% ethanol, stained with 0.1% crystal violet and photographed in four fields to cover the entire area. Error bars
represent the standard error of three experiments performed in triplicate. (c and d) Rescue of EpCAM expression in MDA-231 cells by cDNA
expression (RES), rescues protein expression (immunoblot) and invasion (matrigel transwell invasion assay).
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Figure 2 EpCAM expression is associated with breast cancer invasion in vivo in a breast cancer xenograft model. (a and b) MDA-231
breast cancer cells were stably transduced with experimental (sh2) or control (scrambled control shRNA construct (SCR)) shRNA lentiviral
constructs. One × 107 MDA-231 cells were resuspended in matrigel (1:1 ratio by volume) and injected into nude mice (n = 10 per group). The
right flank was injected with MDA-231(SCR) cells and the left flank was injected with MDA-231(sh2) cells. Tumor size was measured by electronic
calipers every thre to five days. Photos at the time of sacrifice demonstrate tumor growth in the right flank but not in the left flank. (c) H&E
evaluation of the tumor site demonstrates that MDA-231(SCR) cells were invading into the surrounding fat, while MDA-231(sh2) tumors were not
invasive. (d) Specific ablation of EpCAM did not impact cell cycle/proliferation of MDA-231 cells when analyzed prior to tumor challenge. The
percentage of cells in each stage of the cell cycle is indicated.
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EpCAM expression is associated with increased AP-1
transcription factor activity in breast cancer cells

To address the potential mechanism(s) underlying the
impact of EpCAM on breast cancer invasion, we used a
luciferase reporter pathway profiling system to measure
the activity of specific transcription factors following
specific ablation of EpCAM expression. In this system,
individual vectors in the profiling system contain the
transcriptional response elements of the transcription

factors of interest upstream of a luciferase reporter.
These reporters are then individually transfected with a
control TK-Renilla construct into cells stably transduced
with control or EpCAM-specific shRNA vectors. In
these studies, we focused on the AP-1 transcription factor, because AP-1 has been shown to be a critical regulator of a complex program of gene expression
contributing to the invasive phenotype [38]. Using this
strategy, we found that specific ablation of EpCAM is
associated with a two-fold or greater reduction in AP-1
transcription factor activity in MDA-231 breast cancer
cells at baseline (Figure 4a), or in the presence of EGF,
or PMA, which are known to induce AP-1 activity [39]
(Figure 4b). Rescue of EpCAM expression using
EpCAM cDNA resistant to RNA interference, or rescue
of EpCAM signaling using recombinant soluble EpCAM
resulted in a dose-dependent rescue of AP-1 transcription factor activity, confirming the specificity and significance of these observations (Figures 4c and 4d).
EpCAM expression is associated with increased
phosphorylation of the AP-1 protein subunit c-Jun

AP-1 can be activated through at least two possible regulatory mechanisms [40,41]. First, transcription of c-Jun
and other AP-1 protein subunits can be rapidly induced,
resulting in increased total protein levels. Second, AP-1
protein subunits can be phosphorylated by mitogen-activated protein kinases (MAPKs), including JNK. In preliminary studies using a multiplex phosphoprotein assay,
specific ablation of EpCAM decreased c-Jun and JNK1
phosphorylation in breast cancer cells (Figure 5a). To
confirm and extend these findings, we specifically
ablated EpCAM in breast cancer cells (CA1a, and MCF-

1000
N o . In v a d e d c e lls

mechanistic studies, we specifically ablated EpCAM
expression using specific shRNA constructs and then
rescued EpCAM expression using EpCAM cDNA constructs resistant to RNA interference as we previously
described [32] (Figures 1c and 1d). In these experiments,
EpCAM rescue in MDA-231 and CA1a breast cancer
cells results in EpCAM overexpression as measured by
immunoblot, and increased invasion, establishing a gainof-function model system.
We used the lentiviral vectors validated above to
determine the impact of EpCAM expression on breast
cancer invasion in vivo, taking advantage of a commonly
used breast cancer xenograft model [34-36]. Specific
ablation of EpCAM expression in MDA-231 breast cancer cells significantly decreases tumor growth following
tumor challenge in nude mice (Figures 2a and 2b). Histological examination of the tumors confirms that specific ablation of EpCAM abrogates the ability of tumors
to invade into surrounding tissues (Figure 2c). Of note,
we and others have observed that depending on the
experimental conditions, EpCAM expression can impact
proliferation [3-5]. Significant changes in proliferation
could impact interpretation of the in vivo tumor challenge studies. However, only minimal changes in cell
cycle (Figure 2d) and proliferation (data not shown)
were observed following specific ablation of EpCAM
expression in MDA-231 breast cancer cells under these
experimental conditions.
Recently, Gires et al. demonstrated that EpCAM is
cleaved by regulated intramembrane proteolysis, resulting in release of the extracellular domain as a soluble
ligand, and translocation of the intracellular domain
(EpICD) into the nucleus [5,37]. In these studies, the
extracellular domain of EpCAM is also able to modulate
EpCAM signaling. We used recombinant soluble extracellular EpCAM (rEpCAM) to rescue EpCAM signaling
following specific ablation of EpCAM. Addition of
rEpCAM to MDA-231 breast cancer cells is able to rescue invasion following specific ablation of EpCAM (Figure 3). Taken together, these findings confirm the
hypothesis that EpCAM expression modulates breast
cancer invasion, with increased EpCAM expression and/
or signaling associated with increased breast cancer
invasion.
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Figure 3 Recombinant extracellular EpCAM rescues breast
cancer invasion in vitro. To evaluate the impact of epithelial cell
adhesion molecule (EpCAM) signaling on breast cancer invasion,
rEpCAM (200 ng/mL) or vehicle was mixed with MDA-231(sh2) cells
and plated on top matrigel chamber. After 48 hours, the cells were
harvested and invasion was evaluated. The results are representative
of two independent experiments.
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Figure 4 EpCAM expression is associated with AP-1 transcription factor activity. Epithelial cell adhesion molecule (EpCAM) expression was
specifically ablated in breast cancer cells using lentiviral constructs, and then rescued by cDNA or recombinant EpCAM. (a) A luciferase reporter
pathway profiling system was used to measure the impact of EpCAM expression on the activity of specific transcription factors. Results from the
pTA (control), activator protein 1 (AP-1) and SRE reporters are shown. AP-1 transcription factor activity was significantly decreased following
specific ablation of EpCAM in MDA-231(sh2) cells. Other transcription factors were evaluated but specific ablation of EpCAM had minimal effect
(data not shown). Stably transduced MDA-231 cells (scrambled control shRNA construct (SCR) and sh2) were plated for 12 hours, then transiently
transfected with the reporters indicated. Luciferase activity was measured 48 hours later. (b) Following this same protocol, the AP-1 reporter was
transfected into stably transduced MDA-231 cells (SCR and sh2). Twelve hours after transfection, AP-1 transcription factor activity was induced
with phorbol-myristate acetate (PMA; 50 ng/mL) or epidermal growth factor (EGF; 10 ng/mL). 12 hours after induction, reporter activity was
measured. (c) AP-1 transcription factor activity is rescued in a dose-dependent fashion by transfection with increasing concentrations of EpCAM
cDNA. MDA-231(sh2) cells were transiently transfected with 200 ng of pcDNA3, or 50 to 200 ng of pCDNA-EpCAM as indicated. The total
amount of DNA was constant at 200 ng, as indicated. (d) AP-1 transcription factor activity is rescued in a dose-dependent fashion by
recombinant EpCAM. Twelve hours after transient transfection with the AP-1 reporter, the indicated doses of rEpCAM were added to MDA-231
(sh2) cells. Fourteen hours after addition of rEpCAM, AP-1 reporter activity was measured. The results are representative of at least two
independent experiments.

7), and then measured the levels of total and phosphorylated c-Jun by protein immunoblot and densitometry. In
CA1a and MCF-7 breast cancer cells, specific ablation
of EpCAM decreased phosphorylated c-Jun, but had no
significant impact on total c-Jun (Figure 5b). A similar
decrease in phosphorylated but not total ATF2 was also
observed (data not shown). We also evaluated total and
phosphorylated c-Jun following rescue of EpCAM signaling by rEpCAM. Increasing doses of rEpCAM rescued phosphorylated c-Jun following specific ablation of
EpCAM in CA1a cells (Figure 5c). Taken together, these
studies suggest that phosphorylation of existing AP-1

protein subunits contributes to modulation of AP-1
transcription factor activity following specific ablation or
rescue of EpCAM expression and/or signaling.
The JNK signal transduction pathway contributes to
EpCAM-dependent AP-1 transcription factor activity

AP-1 is a major target of the JNK signal transduction
pathway, and activated JNK can bind and phosphorylate
c-Jun. To directly evaluate the impact of EpCAM
expression on JNK phosphorylation, we manipulated
EpCAM expression and then measured JNK phosphorylation by immunoblot and densitometry. Specific
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ablation of EpCAM results in a significant decrease in
JNK phosphorylation in CA1a and MCF-7 breast cancer
cells (Figure 6a). To evaluate the contribution of the
JNK signal transduction pathway in more detail, we
used pharmacologic inhibitors of the JNK signal transduction pathway. Specific ablation of EpCAM is associated with a decrease in AP-1 transcription factor
activity, and this decrease can be rescued in a dosedependent fashion with rEpCAM (Figure 6a). Addition
of SP600125, an anthrapyrazolone inhibitor of JNK [42],
abrogates the increase in AP-1 transcription factor activity induced by rEpCAM, suggesting a role for the JNK
signal transduction pathway. To confirm and extend
these findings we used constitutively active genetic constructs corresponding to MAP kinases in the JNK signal
transduction pathway (MEKK1-MKK7-JNK). Constitutively active JNK MAPK constructs rescued c-Jun phosphorylation (Figure 6c) and AP-1 transcription factor
activity (Figure 6d) following specific ablation of
EpCAM in MCF-7 breast cancer cells. Taken together
these studies provide evidence that EpCAM expression
can modulate the JNK signal transduction pathway, and
AP-1 transcription factor activity.

0.99

c-Jun
c-Jun
Figure 5 EpCAM expression is associated with phosphorylation
of the AP-1 transcription factor protein subunit c-Jun. (a)
Specific ablation of epithelial cell adhesion molecule (EpCAM) is
associated with decreased c-Jun phosphorylation as measured by
multiplex phosphoprotein assay. Stably transduced CA1a cells
(scrambled control shRNA construct (SCR) and sh2) were induced
with epidermal growth factor (EGF), and phosphorylation was
measured using a multiplex phosphoprotein assay. Relative levels of
phosphorylated (p)-AKT, p-c-Jun, and p-JNK were measured by flow
cytometry and expressed as mean fluorescence intensity (MFI). Error
bars represent standard error. (b) Specific ablation of EpCAM is
associated with decreased c-Jun phosphorylation as measured by
phosphoprotein immunoblot. Stably transduced CA1a and MCF-7
cells (SCR and sh2) were serum-starved for six hours. The cells were
treated with 20 μM anisomycin for 15 minutes and 30 μg of the cell
lysate was analyzed with antibodies recognizing EpCAM, superoxide
dismutase (SOD, loading control), p-c-Jun-63, or total c-Jun. Relative
band density was quantified using ImageJ software, with the results
indicated below the relevant band. (c) Recombinant EpCAM is
capable of rescuing c-Jun phosphorylation in CA1a(sh2) cells. CA1a
(sh2) cells were serum-starved for six hours and then treated with
rEpCAM at concentrations of 50, 100, and 200 ng/mL for two hours.
The cells were then stimulated with anisomycin for 10 minutes. A
30 μg sample of each cell lysate was analyzed for p-c-Jun and total
c-Jun. Relative band density was quantified using ImageJ software,
with the results indicated. The results are representative of two
independent experiments.

AP-1 is considered to be a central transcription factor in
the regulation of cancer invasion [38]. To directly assess
the functional contribution of AP-1 in EpCAMmediated breast cancer invasion, we specifically ablated
EpCAM expression in CA1a breast cancer cells, and
then rescued AP-1 transcription factor activity using a
constitutively active c-Jun genetic construct [43]. c-Jun
expression is able to efficiently rescue AP-1 transcription factor activity (data not shown) and invasion (Figure 7a), suggesting that the AP-1 protein subunit c-Jun
is a key downstream mediator of EpCAM biology, contributing to EpCAM-dependent breast cancer invasion.
EpCAM expression modulates the expression of AP-1
target genes known to be involved in cancer invasion

To confirm the impact of EpCAM on AP-1 target gene
expression, we specifically ablated EpCAM and then
analyzed more than 120 AP-1 target genes known to be
involved in cancer invasion using quantitative RT-PCR
[38]. We identified more than 30 genes that were
impacted at the mRNA level by specific ablation of
EpCAM. To confirm these results, EpCAM expression
was specifically ablated in CA1a breast cancer cells, and
then rescued with increasing doses of EpCAM cDNA.
Increasing EpCAM expression is associated with a dosedependent increase in the expression of the AP-1 target
genes CTSL1, Autotaxin and ARP2/3 (Figure 8). These
studies provide additional support for the hypothesis
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Figure 6 The MEKK1/MKK7/JNK signal transduction pathway contributes to EpCAM-dependent AP-1 transcription factor activity. (a)
Pharmacologic inhibition of c-Jun N-terminal kinase (JNK) abrogates recombinant soluble extracellular epithelial cell adhesion molecule
(rEpCAM)-mediated rescue of activator protein 1 (AP-1) transcription factor activity. Stably transduced CA1a (scrambled control shRNA construct
(SCR) and sh2) cells were transiently transfected with AP-1 and control luciferase reporters. Six hours after transfection, cells were treated with
SP600125 (JNK inhibitor) at 10 μM and 20 μM for one hour followed by addition of rEpCAM. Luciferase reporter activity was measured 16 hours
later. (b) To directly evaluate JNK phosphorylation, SCR and sh2 CA1a and MCF-7 cells were serum starved for 12 hours, stimulated with 20 μM
anisomycin for 10 minutes, and then immunoprecipitated overnight with a JNK antibody. JNK phosphorylation was evaluated by immunoblot
using antibodies specific for p-JNK1/2 and total JNK1. Relative band density was quantified using ImageJ software, with the results indicated. (c)
Constitutively active genetic constructs corresponding to mitogen activated protein (MAP) kinases in the JNK signal transduction pathway
rescued c-Jun phosphorylation and AP-1 transcription factor activity following specific ablation of EpCAM in MCF-7 breast cancer cells. Stably
transduced SCR or sh2 MCF-7 cells were transiently transfected with plasmids encoding HA-MEKK1, FLAG-MKK7-JNK1, FLAG-MKK7, and FLAGJNK1. After 16 hours, cells were analyzed by immunoblot for c-Jun phosphorylation. Relative band density was quantified using ImageJ software,
with the results indicated. (d) Duplicate samples were transiently transfected with control and AP-1 luciferase reporters, and AP-1 transcription
factor activity was measured. (e) Expression of HA-MEKK1, FLAG-MKK7-JNK1, FLAG-MKK7, and FLAG-JNK1 was confirmed by immunoblot with
antibodies specific for the indicated protein tag (HA or FLAG). The results are representative of two independent experiments. For AP-1 reporter
assay in Figure a and d, P < 0.05 were considered to be statistically significant when compared between SCR, sh2 (*) and sh2, sh2 treated/
transfected cells (**).
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Figure 7 Forced overexpression of c-Jun rescues breast cancer
invasion in vitro following specific ablation of EpCAM. (a) Stably
transduced CA1a cells (sh2), were transiently transfected with
pcDNA or c-Jun constructs. After 24 hours, invasion was assessed
using a matrigel transwell invasion assay. (b) Transfected cells were
analyzed for c-Jun mRNA expression by RT-PCR. Actin mRNA
expression served as a control for RT-PCR conditions. The results are
representative of two independent experiments. EpCAM, epithelial
cell adhesion molecule.

that EpCAM expression modulates AP-1 transcription
factor activity.

Discussion
EpCAM is a cell-surface glycoprotein that is overexpressed on the majority of epithelial cancers, including
breast cancer. However, the functional role of EpCAM
in cancer invasion remains controversial. In this study
we focused on the role of EpCAM in breast cancer invasion. We confirm that EpCAM expression is associated
with increased breast cancer invasion in vitro and in
vivo, and demonstrate for the first time that EpCAM
expression is capable of modulating the JNK/AP-1 signal
transduction pathway. In functional rescue experiments,
we demonstrate that forced overexpression of c-Jun is
capable of rescuing breast cancer invasion following specific ablation of EpCAM, confirming that AP-1 is a key
downstream mediator of EpCAM-dependent breast cancer invasion.
Recently, Munz et al. demonstrated that de novo
induction of EpCAM expression is associated with the

Figure 8 EpCAM expression modulates expression of AP-1
target genes known to be involved in cancer invasion. MDA231 cells were transiently transfected with control and epithelial cell
adhesion molecule (EpCAM) cDNA expression constructs and
allowed to stabilize for 24 hours. The cells were then serum-starved
for 16 hours, and then stimulated with 10% FBS DMEM growth
media for two hours. RNA was extracted using RNeasy (Qiagen).
Two micrograms of RNA was reverse transcribed and 40 ng
equivalent cDNA was used for each assay in triplicate. Activator
protein 1 (AP-1) target genes CTSL1, Autotaxin, and ARP2/3 were
analyzed using real-time PCR. Relative expression was quantified
using the [delta] [delta] Ct method with 18S rRNA as a control. The
results are representative of at least two independent experiments.

rapid upregulation of c-myc expression in epithelial
cells, strongly suggesting that EpCAM can function as a
signaling molecule [3]. In their studies the most dramatic phenotype of forced EpCAM expression was on
cell cycle and proliferation, consistent with the known
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role of c-myc in regulating genes involved in control of
the cell cycle. However, we and others have found that
the most dramatic phenotype associated with manipulation of EpCAM expression in human cancers is altered
invasion [4,7,29,30]. This suggests that other signaling
pathways may also be modulated by EpCAM expression/signaling. Our finding that EpCAM differentially
regulates the JNK/AP-1 signal transduction pathway is
particularly relevant in this context. The AP-1 transcription factor is a heterodimeric protein composed of proteins belonging to the c-Jun, c-Fos, ATF, and JDP
families [39]. AP-1 is activated in response to a variety
of stimuli, including cytokines, growth factors, stress,
and infection, and is considered to be a central transcription factor in the regulation of cell invasion [38].
Of particular note, AP-1 appears to be overexpressed in
breast cancer [44,45], and is currently being evaluated as
a target for molecular therapy in this disease [46-48].
Recent studies have focused specifically on the role of cJun in breast cancer. In primary breast cancers, activated
c-Jun is present at the invasive front, and is associated
with proliferation and angiogenesis [45]. In addition,
recent studies confirm the role of c-Jun in breast cancer
invasion in vitro [49], and in spontaneous tumors
derived from genetically engineered mice [50]. Despite
the central role of AP-1 as a regulator of invasion, our
studies do not exclude the possibility that other signaling pathways are modulated by EpCAM, and may also
contribute to the regulation of invasion in breast cancer.
Recently, Gostner et al. demonstrated that specific ablation of EpCAM in MDA-231 cells may modulate the
Wnt signaling pathway [51].
Maetzel et al. recently demonstrated that EpCAM is
cleaved by regulated intramembrane proteolysis in a
hypopharyngeal cancer cell line, resulting in the release
of the extracellular portion of the molecule, EpEX, and
the intracellular domain, EpIC [5]. In their studies, EpIC
localizes to the nucleus, and interacts with FHL2 and bcatenin to promote Wnt signaling. Our studies confirm
the importance of the extracellular domain of EpCAM
in EPCAM signaling; addition of recombinant extracellular EpCAM rescues breast cancer invasion, AP-1 transcription factor activity, and c-Jun phosphorylation in a
dose-dependent fashion following specific ablation of
EpCAM. However, we have been unable to rescue invasion by forced overexpression of EpIC (data not shown).
FHL2 is known to be an inducible co-activator of AP-1
[52], and one hypothesis is EpCAM expression/signaling
results in EpIC translocation to the nucleus and subsequent interaction with FHL2 and AP-1 proteins to
increase AP-1 signaling. Alternatively, EpCAM expression/signaling may modulate the JNK signal transduction pathway directly or indirectly, leading to c-jun
phosphorylation and AP-1 activation. In support of this
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latter hypothesis, cell adhesion molecules such as
ICAM-1 are known to modulate the JNK/AP-1 signaling
pathway. Although our data does suggest that the JNK/
AP-1 signaling pathway is modulated, these hypotheses
are not mutually exclusive, and additional studies are
ongoing to determine how EpCAM signaling impacts
AP-1 transcription factor activity.
Finally, EpCAM represents an attractive target for
molecular therapy in epithelial carcinomas. EpCAM is
overexpressed in the majority of epithelial carcinomas,
and there are currently a number of different molecular therapies under development [1]. The results of the
studies presented here have important implications for
the design and application of these molecular therapies. The most important implication is that molecular
therapies under investigation should be evaluated for
their ability to influence EpCAM-mediated signaling
pathways, as recent studies suggest that monoclonal
antibodies targeting EpCAM may alter EpCAM signaling [53]. Molecular therapies capable of interfering
with EpCAM-mediated signaling may find particular
success in the treatment of breast cancer, where
EpCAM expression is associated with increased invasion and poor prognosis.

Conclusions
EpCAM expression is associated with increased breast
cancer invasion. In mechanistic studies, we demonstrate that EpCAM expression modulates the JNK signal transduction pathway, and AP-1 transcription
factor activity in breast cancer cells. Functional studies
confirm that AP-1 is a key downstream mediator of
EpCAM biology, contributing to EpCAM-dependent
breast cancer invasion. Further study of EpCAMmediated signaling pathways is necessary to facilitate
the rational design and application of molecular therapies targeting EpCAM.
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